| Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? |
Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year. |
zacks.com |
2025-05-15 14:46:34 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen |
Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile SEATTLE , May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer. Key Findings: Primary feasibility goal surpassed – 95 percent of participants (19/20) completed at least 75 percent of planned dosing, far exceeding the predefined 75 percent threshold. |
prnewswire.com |
2025-05-14 12:15:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update |
Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE , May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments. First Quarter 2025 Highlights: Announced Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa announced plans to target metastatic breast cancer as its lead program for (Z)-endoxifen. |
prnewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio |
SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations. |
globenewswire.com |
2025-04-30 12:45:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 |
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneering Phase 3 clinical study titled SMART 2.0. The proposed trial would investigate the potential of oral (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition, to significantly reduce interval breast cancer in women identified as high-risk through advanced mammographic screening techniques. The proposed SMART 2.0 study was presented at the American Association for Cancer Research (AACR) Annual Meeting and represents a future research program and potential partnership opportunity to advance this critical initiative for women at high risk of breast cancer. |
globenewswire.com |
2025-04-29 12:45:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio |
SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations. |
globenewswire.com |
2025-04-22 12:45:00 |
Czytaj oryginał (ang.) |
| Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer |
CAMBRIDGE, Mass. , April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). |
prnewswire.com |
2025-04-10 12:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy |
Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-28 15:00:29 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript |
Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and CEO Heather Rees - CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good morning, everyone, and welcome to the Atossa Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-25 12:05:16 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update |
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results |
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time |
globenewswire.com |
2025-03-20 11:13:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications |
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes that pursuing a metastatic indication may offer a more efficient regulatory pathway to deliver (Z)-endoxifen to women in urgent need, and simultaneously plans to work with the FDA to advance additional indications, such as breast cancer prevention and neoadjuvant therapy, that often require larger and longer clinical trials. |
globenewswire.com |
2025-03-11 10:15:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care |
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention (CDC). This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients across New York City. |
globenewswire.com |
2025-02-05 10:00:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. |
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board's (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the “'334 patent”). |
globenewswire.com |
2025-01-30 10:17:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 |
SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company's clinical programs and recent events. The full text of the letter follows: |
globenewswire.com |
2025-01-23 10:15:00 |
Czytaj oryginał (ang.) |
| Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? |
Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year. |
zacks.com |
2024-12-20 12:40:45 |
Czytaj oryginał (ang.) |
| ATOS Digital Transformation Strategy Profile 2024: Accelerators, Incubators and Innovation Programs |
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: ATOS SE 2024" company profile has been added to ResearchAndMarkets.com's offering. |
globenewswire.com |
2024-12-19 07:59:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium |
Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer Treatments Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer Treatments |
globenewswire.com |
2024-12-12 10:15:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density |
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer |
globenewswire.com |
2024-12-11 10:15:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium |
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024). EVANGELINE is a randomized Phase 2 non-inferiority study investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with estrogen receptor-positive (ER+)/HER2-negative breast cancer. |
globenewswire.com |
2024-12-10 11:05:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research |
Novel Compounds Demonstrate Promising Anti-Tumor Activity in Estrogen Receptor-Positive (ERα+) Breast Cancer, Including Endocrine-Resistant Tumors Novel Compounds Demonstrate Promising Anti-Tumor Activity in Estrogen Receptor-Positive (ERα+) Breast Cancer, Including Endocrine-Resistant Tumors |
globenewswire.com |
2024-12-09 10:15:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research |
Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer |
globenewswire.com |
2024-11-21 10:30:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium |
Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference Detailed results from the KARISMA-Endoxifen trial demonstrating (Z)-endoxifen's ability to significantly reduce mammographic breast density to be featured at conference |
globenewswire.com |
2024-11-20 10:30:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update |
SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced financial results for the fiscal quarter ended September 30, 2024, and provided an update on recent company developments. |
globenewswire.com |
2024-11-12 10:30:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development |
Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast Cancer Therapies Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa's Mission in Developing Innovative Breast Cancer Therapies |
globenewswire.com |
2024-11-05 10:30:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: |
(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies |
globenewswire.com |
2024-11-04 08:30:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer |
(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial |
globenewswire.com |
2024-10-31 10:15:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? |
Here is how Atossa Genetics Inc. (ATOS) and Cardinal Health (CAH) have performed compared to their sector so far this year. |
zacks.com |
2024-10-28 12:40:40 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer |
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence (AI)-based risk model with promising emerging therapies that may help prevent breast cancer in high-risk patients. BIO-Europe 2024 is scheduled for November 4-6, 2024, in Stockholm, Sweden. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. |
globenewswire.com |
2024-10-21 12:30:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit |
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. |
globenewswire.com |
2024-10-14 21:08:00 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum |
SEATTLE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its recognition and support of Breast Cancer Awareness Month this October; highlighting the importance of increasing awareness, advancing research, and driving progress toward innovative treatments for breast cancer. Approximately one in eight women will be diagnosed with breast cancer in their lifetime, so this annual campaign serves as a powerful reminder of the ongoing need for education, early detection, prevention, and access to effective treatment options. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. |
globenewswire.com |
2024-10-01 12:30:00 |
Czytaj oryginał (ang.) |
| Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? |
Here is how Atossa Genetics Inc. (ATOS) and CorMedix (CRMD) have performed compared to their sector so far this year. |
zacks.com |
2024-09-19 14:46:31 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer |
FDA Update to Mammography Regulations in MQSA Final Rule is Effective Today FDA Update to Mammography Regulations in MQSA Final Rule is Effective Today |
globenewswire.com |
2024-09-10 12:30:00 |
Czytaj oryginał (ang.) |
| Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? |
Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year. |
zacks.com |
2024-09-03 14:40:54 |
Czytaj oryginał (ang.) |
| Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference |
SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event, scheduled for September 9-11, 2024, will be held both in-person and virtually. |
globenewswire.com |
2024-09-03 12:30:00 |
Czytaj oryginał (ang.) |